Utility of immune response-derived biomarkers in the differential diagnosis of inflammatory disorders

Journal of Infection

Volumn 72, Issue 1, 2016, Pages 1-18

  ten Oever, Jaap ^a   Netea, Mihai G ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Diagnosis; Immunology; Non infectious inflammatory disorder; Sepsis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; INFLAMMATION; SEPSIS;

ADULT; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; SEPSIS;

EID: 84955347352     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.09.007     Document Type: Review

References (100)

1. Kumar A., Roberts D., Wood K.E., Light B., Parrillo J.E., Sharma S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596. 10.1097/01.CCM.0000217961.75225.E9.
2. Houck P.M., Bratzler D.W., Nsa W., Ma A., Bartlett J.G. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164(6):637-644. 10.1001/archinte.164.6.637.
3. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49(9):3640-3645. 10.1128/AAC.49.9.3640-3645.2005.
4. de Kruif M.D., Limper M., Gerritsen H., Spek C.A., Brandjes D.P., ten Cate H., et al. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med 2010, 38(2):457-463. 10.1097/CCM.0b013e3181b9ec33.
5. Altman D.G., Bland J.M. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994, 188(6948):309. http://www.ncbi.nlm.nih.gov/pubmed/8044101.
6. Fischer J.E., Bachmann L.M., Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003, 29(7):1043-1051. 10.1007/s00134-003-1761-8.
7. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8(7):543-548. 10.1016/j.autrev.2009.01.013.
8. Wenz B., Gennis P., Canova C., Burns E.R. The clinical utility of the leukocyte differential in emergency medicine. Am J Clin Pathol 1986, 86(3):298-303. http://www.ncbi.nlm.nih.gov/pubmed/3751994.
9. Cavallazzi R., Bennin C.L., Hirani A., Gilbert C., Marik P.E. Is the band count useful in the diagnosis of infection? an accuracy study in critically ill patients. J Intensive Care Med 2010, 25(6):353-357. 10.1177/0885066610377980.
10. van der Geest P.J., Mohseni M., Brouwer R., van der Hoven B., Steyerberg E.W., Groeneveld A.B. Immature granulocytes predict microbial infection and its adverse sequelae in the intensive care unit. J Crit Care 2014, 29(4):523-527. 10.1016/j.jcrc.2014.03.033.
11. Potasman I., Grupper M. Leukemoid reaction: spectrum and prognosis of 173 adult patients. Clin Infect Dis 2013, 57(11):e177-81. 10.1093/cid/cit562.
12. Nuutila J., Jalava-Karvinen P., Hohenthal U., Kotilainen P., Pelliniemi T.T., Nikoskelainen J., et al. A rapid flow cytometric method for distinguishing between febrile bacterial and viral infections. J Microbiol Methods 2013, 92(1):64-72. 10.1016/j.mimet.2012.11.005.
13. Chalupa P., Beran O., Herwald H., Kasprikova N., Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection 2011, 39(5):411-417. 10.1007/s15010-011-0126-4.
14. Nierhaus A., Klatte S., Linssen J., Eismann N.M., Wichmann D., Hedke J., et al. Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis-a prospective, observational study. BMC Immunol 2013, 14:8. 10.1186/1471-2172-14-8.
15. Garnacho-Montero J., Huici-Moreno M.J., Gutierrez-Pizarraya A., Lopez I., Marquez-Vacaro J.A., Macher H., et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care 2014, 18(3):R116. 10.1186/cc13908.
16. Abidi K., Khoudri I., Belayachi J., Madani N., Zekraoui A., Zeggwagh A.A., et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care 2008, 12(2):R59. 10.1186/cc6883.
17. Shaaban H., Daniel S., Sison R., Slim J., Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital?. J Crit Care 2010, 25(4):570-575. 10.1016/j.jcrc.2010.03.002.
18. Smithson A., Perello R., Nicolas J.M. Is eosinopenia a reliable marker of sepsis?. Crit Care 2009, 13(3):409. 10.1186/cc7877.
19. Elghetany M.T. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 2002, 28(2):260-274. http://www.ncbi.nlm.nih.gov/pubmed/12064921.
20. van der Meer W., Pickkers P., Scott C.S., van der Hoeven J.G., Gunnewiek J.K. Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia. J Endotoxin Res 2007, 13(2):94-100. 10.1177/0968051907079101.
21. Li S., Huang X., Chen Z., Zhong H., Peng Q., Deng Y., et al. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection: a meta-analysis. Int J Infect Dis 2013, 17(1):e12-23. 10.1016/j.ijid.2012.07.017.
22. Gibot S., Bene M.C., Noel R., Massin F., Guy J., Cravoisy A., et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012, 186(1):65-71. 10.1164/rccm.201201-0037OC.
23. Matsui T., Ohsumi K., Ozawa N., Shimada K., Sumitomo S., Shimane K., et al. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol 2006, 33(12):2416-2424. http://www.ncbi.nlm.nih.gov/pubmed/17080517.
24. Jalava-Karvinen P., Hohenthal U., Laitinen I., Kotilainen P., Rajamaki A., Nikoskelainen J., et al. Simultaneous quantitative analysis of Fc gamma RI (CD64) and CR1 (CD35) on neutrophils in distinguishing between bacterial infections, viral infections, and inflammatory diseases. Clin Immunol 2009, 133(3):314-323. 10.1016/j.clim.2009.08.003.
25. Mokuda S., Doi O., Takasugi K. Simultaneous quantitative analysis of the expression of CD64 and CD35 on neutrophils as markers to differentiate between bacterial and viral infections in patients with rheumatoid arthritis. Mod Rheumatol 2012, 22(5):750-757. 10.1007/s10165-011-0587-4.
26. Hussein O.A., El-Toukhy M.A., El-Rahman H.S. Neutrophil CD64 expression in inflammatory autoimmune diseases: its value in distinguishing infection from disease flare. Immunol Invest 2010, 39(7):699-712. 10.3109/08820139.2010.491520.
27. Allen E., Bakke A.C., Purtzer M.Z., Deodhar A. Neutrophil CD64 expression: distinguishing acute inflammatory autoimmune disease from systemic infections. Ann Rheum Dis 2002, 61(6):522-525. http://www.ncbi.nlm.nih.gov/pubmed/12006325.
28. Agrawal A., Singh P.P., Bottazzi B., Garlanda C., Mantovani A. Pattern recognition by pentraxins. Adv Exp Med Biol 2009, 653:98-116. http://www.ncbi.nlm.nih.gov/pubmed/19799114.
29. Gendrel D., Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000, 19(8):679-687. quiz 88. http://www.ncbi.nlm.nih.gov/pubmed/10959733.
30. ten Oever J., Tromp M., Bleeker-Rovers C.P., Joosten L.A., Netea M.G., Pickkers P., et al. Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections. J Infect 2012, 65(6):490-495. 10.1016/j.jinf.2012.08.004.
31. Menendez R., Sahuquillo-Arce J.M., Reyes S., Martinez R., Polverino E., Cilloniz C., et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012, 141(6):1537-1545. 10.1378/chest.11-1446.
32. Kruger S., Ewig S., Papassotiriou J., Kunde J., Marre R., von Baum H., et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65. 10.1186/1465-9921-10-65.
33. Ip M., Rainer T.H., Lee N., Chan C., Chau S.S., Leung W., et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis 2007, 59(2):131-136. 10.1016/j.diagmicrobio.2007.04.019.
34. Rainer T.H., Chan C.P., Leung M.F., Leung W., Ip M., Lee N., et al. Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections. J Infect 2009, 58(2):123-130. 10.1016/j.jinf.2008.11.007.
35. Pfister R., Kochanek M., Leygeber T., Brun-Buisson C., Cuquemelle E., Machado M.B., et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care 2014, 18(2):R44. 10.1186/cc13760.
36. Kofoed K., Andersen O., Kronborg G., Tvede M., Petersen J., Eugen-Olsen J., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11(2):R38. 10.1186/cc5723.
37. Wu M.H., Lin C.C., Huang S.L., Shih H.M., Wang C.C., Lee C.C., et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir Viruses 2013, 7(3):349-355. 10.1111/j.1750-2659.2012.00386.x.
38. Paiva M.B., Botoni F.A., Teixeira A.L., Miranda A.S., Oliveira C.R., Abrahao Jde O., et al. The behavior and diagnostic utility of procalcitonin and five other inflammatory molecules in critically ill patients with respiratory distress and suspected 2009 influenza a H1N1 infection. Clin (Sao Paulo) 2012, 67(4):327-334. http://www.ncbi.nlm.nih.gov/pubmed/22522757.
39. Masia M., Gutierrez F., Llorca B., Navarro J.C., Mirete C., Padilla S., et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004, 50(9):1661-1664. 10.1373/clinchem.2004.031294.
40. Kang Y.A., Kwon S.Y., Yoon H.I., Lee J.H., Lee C.T. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009, 24(4):337-342. 10.3904/kjim.2009.24.4.337.
41. Ugajin M., Miwa S., Shirai M., Ohba H., Eifuku T., Nakamura H., et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011, 37(2):371-375. 10.1183/09031936.00011910.
42. Liam C.K., Pang Y.K., Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006, 11(6):786-792. 10.1111/j.1440-1843.2006.00947.x.
43. Schuetz P., Christ-Crain M., Thomann R., Falconnier C., Wolbers M., Widmer I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302(10):1059-1066. 10.1001/jama.2009.1297.
44. Martini A., Gottin L., Menestrina N., Schweiger V., Simion D., Vincent J.L. Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010, 60(6):425-430. 10.1016/j.jinf.2010.03.003.
45. Markova M., Brodska H., Malickova K., Valkova V., Cetkovsky P., Kolar M., et al. Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Support Care Cancer 2013, 21(10):2733-2742. 10.1007/s00520-013-1844-1.
46. Petrikkos G.L., Christofilopoulou S.A., Tentolouris N.K., Charvalos E.A., Kosmidis C.J., Daikos G.L. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005, 24(4):272-275. 10.1007/s10096-005-1312-z.
47. Charles P.E., Dalle F., Aho S., Quenot J.P., Doise J.M., Aube H., et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006, 32(10):1577-1583. 10.1007/s00134-006-0306-3.
48. Wacker C., Prkno A., Brunkhorst F.M., Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13(5):426-435. 10.1016/S1473-3099(12)70323-7.
49. Kjaergaard A.G., Rodgaard-Hansen S., Dige A., Krog J., Moller H.J., Tonnesen E. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients. PLoS One 2014, 9(3):e92331. 10.1371/journal.pone.0092331.
50. Ruokonen E., Ilkka L., Niskanen M., Takala J. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002, 46(4):398-404. http://www.ncbi.nlm.nih.gov/pubmed/11952440.
51. Gaini S., Koldkjaer O.G., Pedersen C., Pedersen S.S. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006, 10(2):R53. 10.1186/cc4866.
52. Tsalik E.L., Jaggers L.B., Glickman S.W., Langley R.J., van Velkinburgh J.C., Park L.P., et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med 2012, 43(1):97-106. 10.1016/j.jemermed.2011.05.072.
53. Wu J.Y., Lee S.H., Shen C.J., Hsieh Y.C., Yo P.H., Cheng H.Y., et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012, 64(9):3034-3042. 10.1002/art.34512.
54. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984, 160(1):310-316. http://www.ncbi.nlm.nih.gov/pubmed/6429267.
55. Hamerlinck F.F. Neopterin: a review. Exp Dermatol 1999, 8(3):167-176. http://www.ncbi.nlm.nih.gov/pubmed/10389633.
56. te Witt R., Hassing R.J., Petit P.P., van Belkum A., van Genderen P.J. Procalcitonin and neopterin levels do not accurately distinguish bacterial from viral infections in ill-returned travellers with fever. Trans R Soc Trop Med Hyg 2012, 106(4):264-266. 10.1016/j.trstmh.2012.01.001.
57. Moller H.J., Peterslund N.A., Graversen J.H., Moestrup S.K. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002, 99(1):378-380. http://www.ncbi.nlm.nih.gov/pubmed/11756196.
58. Moller H.J. Soluble CD163. Scand J Clin Lab Invest 2012, 72(1):1-13. 10.3109/00365513.2011.626868.
59. Gaini S., Koldkjaer O.G., Pedersen S.S., Pedersen C., Moestrup S.K., Moller H.J. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS 2006, 114(2):103-111. 10.1111/j.1600-0463.2006.apm_341.x.
60. Knudsen T.B., Larsen K., Kristiansen T.B., Moller H.J., Tvede M., Eugen-Olsen J., et al. Diagnostic value of soluble CD163 serum levels in patients suspected of meningitis: comparison with CRP and procalcitonin. Scand J Infect Dis 2007, 39(6-7):542-553. 10.1080/00365540601113685.
61. Rathinam V.A., Fitzgerald K.A. Inflammasomes and anti-viral immunity. J Clin Immunol 2010, 30(5):632-637. 10.1007/s10875-010-9431-4.
62. Ahmad R., Sindhu S.T., Toma E., Morisset R., Ahmad A. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. J Virol 2002, 76(24):12448-12456. http://www.ncbi.nlm.nih.gov/pubmed/12438570.
63. Mustafa A.S., Elbishbishi E.A., Agarwal R., Chaturvedi U.C. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2001, 30(3):229-233. http://www.ncbi.nlm.nih.gov/pubmed/11335143.
64. ten Oever J., Riza A., Sabou M., Cismaru C., Netea M.G., Slavcovici A. Characterization of the acute inflammatory response in measles infection. J Pediatric Infect Dis Soc 2014, 3:197-200.
65. van de Veerdonk F.L., Wever P.C., Hermans M.H., Fijnheer R., Joosten L.A., van der Meer J.W., et al. IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. J Infect Dis 2012, 206(2):197-201. 10.1093/infdis/jis335.
66. van de Berg P.J., Heutinck K.M., Raabe R., Minnee R.C., Young S.L., van Donselaar-van der Pant K.A., et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis 2010, 202(5):690-699. 10.1086/655472.
67. Haran J.P., Buglione-Corbett R., Lu S. Cytokine markers as predictors of type of respiratory infection in patients during the influenza season. Am J Emerg Med 2013, 31(5):816-821. 10.1016/j.ajem.2013.01.030.
68. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164(3):396-402. 10.1164/ajrccm.164.3.2009052.
69. Balc I.C., Sungurtekin H., Gurses E., Sungurtekin U., Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003, 7(1):85-90. http://www.ncbi.nlm.nih.gov/pubmed/12617745.
70. Uusitalo-Seppala R., Koskinen P., Leino A., Peuravuori H., Vahlberg T., Rintala E.M. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scand J Infect Dis 2011, 43(11-12):883-890. 10.3109/00365548.2011.600325.
71. Gibot S., Kolopp-Sarda M.N., Bene M.C., Bollaert P.E., Lozniewski A., Mory F., et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004, 200(11):1419-1426. 10.1084/jem.20040708.
72. Phua J., Koay E.S., Zhang D., Tai L.K., Boo X.L., Lim K.C., et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 2006, 28(4):695-702. 10.1183/09031936.06.00005606.
73. Porfyridis I., Plachouras D., Karagianni V., Kotanidou A., Papiris S.A., Giamarellou H., et al. Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis 2010, 10:286. 10.1186/1471-2334-10-286.
74. How C.K., Hou S.K., Shih H.C., Yen D.H., Huang C.I., Lee C.H., et al. Usefulness of triggering receptor expressed on myeloid cells-1 in differentiating between typical and atypical community-acquired pneumonia. Am J Emerg Med 2011, 29(6):626-631. 10.1016/j.ajem.2010.01.010.
75. Wu Y., Wang F., Fan X., Bao R., Bo L., Li J., et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012, 16(6):R229. 10.1186/cc11884.
76. Hou Y.Q., Xu P., Zhang M., Han D., Peng L., Liang D.Y., et al. Serum decoy receptor 3, a potential new biomarker for sepsis. Clin Chim Acta 2012, 413(7-8):744-748. 10.1016/j.cca.2012.01.007.
77. Kim S., Mi L., Zhang L. Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagn Microbiol Infect Dis 2012, 73(4):312-317. 10.1016/j.diagmicrobio.2012.04.008.
78. Zobel K., Martus P., Pletz M.W., Ewig S., Prediger M., Welte T., et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med 2012, 12:6. 10.1186/1471-2466-12-6.
79. Blairon L., Wittebole X., Laterre P.F. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis 2003, 187(2):287-291. 10.1086/346046.
80. Gille-Johnson P., Hansson K.E., Gardlund B. Clinical and laboratory variables identifying bacterial infection and bacteraemia in the emergency department. Scand J Infect Dis 2012, 44(10):745-752. 10.3109/00365548.2012.689846.
81. Meynaar I.A., Droog W., Batstra M., Vreede R., Herbrink P. In critically Ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011, 2011:594645. 10.1155/2011/594645.
82. Ratzinger F., Schuardt M., Eichbichler K., Tsirkinidou I., Bauer M., Haslacher H., et al. Utility of sepsis biomarkers and the infection probability score to discriminate sepsis and systemic inflammatory response syndrome in standard care patients. PLoS One 2013, 8(12):e82946. 10.1371/journal.pone.0082946.
83. Yaegashi Y., Shirakawa K., Sato N., Suzuki Y., Kojika M., Imai S., et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11(5):234-238. 10.1007/s10156-005-0400-4.
84. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012, 18(6):891-897. 10.1007/s10156-012-0435-2.
85. Ulla M., Pizzolato E., Lucchiari M., Loiacono M., Soardo F., Forno D., et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013, 17(4):R168. 10.1186/cc12847.
86. Liu B., Chen Y.X., Yin Q., Zhao Y.Z., Li C.S. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care 2013, 17(5):R244. 10.1186/cc13070.
87. LeBouder E., Rey-Nores J.E., Rushmere N.K., Grigorov M., Lawn S.D., Affolter M., et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003, 171(12):6680-6689. http://www.ncbi.nlm.nih.gov/pubmed/14662871.
88. Ten Oever J., Kox M., van de Veerdonk F.L., Mothapo K.M., Slavcovici A., Jansen T.L., et al. The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunol 2014, 15(1):55. 10.1186/s12865-014-0055-y.
89. ten Oever J., Giamarellos-Bourboulis E.J., van de Veerdonk F.L., Stelma F.F., Simon A., Janssen M., et al. Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur J Clin Microbiol Infect Dis 2013, 32(12):1605-1610. 10.1007/s10096-013-1919-4.
90. Rodgaard-Hansen S., Rafique A., Christensen P.A., Maniecki M.B., Sandahl T.D., Nexo E., et al. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med 2014, 52(3):453-461. 10.1515/cclm-2013-0451.
91. Gazi U., Rosas M., Singh S., Heinsbroek S., Haq I., Johnson S., et al. Fungal recognition enhances mannose receptor shedding through dectin-1 engagement. J Biol Chem 2011, 286(10):7822-7829. 10.1074/jbc.M110.185025.
92. Tromp M., Lansdorp B., Bleeker-Rovers C.P., Gunnewiek J.M., Kullberg B.J., Pickkers P. Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. J Infect 2012, 65(4):292-301. 10.1016/j.jinf.2012.06.004.
93. Ramilo O., Mejias A. Shifting the paradigm: host gene signatures for diagnosis of infectious diseases. Cell Host Microbe 2009, 6(3):199-200. 10.1016/j.chom.2009.08.007.
94. Sutherland A., Thomas M., Brandon R.A., Brandon R.B., Lipman J., Tang B., et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care 2011, 15(3):R149. 10.1186/cc10274.
95. Pankla R., Buddhisa S., Berry M., Blankenship D.M., Bancroft G.J., Banchereau J., et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol 2009, 10(11):R127. 10.1186/gb-2009-10-11-r127.
96. Tang B.M., McLean A.S., Dawes I.W., Huang S.J., Lin R.C. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009, 37(3):882-888. 10.1097/CCM.0b013e31819b52fd.
97. Zaas A.K., Chen M., Varkey J., Veldman T., Hero A.O., Lucas J., et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009, 6(3):207-217. 10.1016/j.chom.2009.07.006.
98. Wellinghausen N., Kochem A.J., Disque C., Muhl H., Gebert S., Winter J., et al. Diagnosis of bacteremia in whole-blood samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol 2009, 47(9):2759-2765. 10.1128/JCM.00567-09.
99. van Bon L., Affandi A.J., Broen J., Christmann R.B., Marijnissen R.J., Stawski L., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370(5):433-443. 10.1056/NEJMoa1114576.
100. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326(7379):41-44. http://www.ncbi.nlm.nih.gov/pubmed/12511463.